Biolex looks for $70M to back new trials

Biolex is also preparing to test the rather chilly IPO waters with an offering designed to raise up to $70 million. The developer's lead candidate, Locteron, is in Phase II for hepatitis C. It has two other therapies headed for the clinic. Biolex lost more than $7 million in the first quarter and says it plans to lose plenty more.

"We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially as we conduct larger-scale trials for our drug candidates, commercialize any approved product candidates, hire additional personnel, and add operational, financial and management information systems," the company said in its prospectus.

- see this release from Biolex
- read the AP report for more info

ALSO: Japan's GNI has set a tentative IPO price. Report

Related Articles:
Biolex pockets $30M for drug discovery work. Report
Biolex touts hep C data. Report
Biolex garners $36M in second round. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.